Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Other Accumulated Expenses (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Other Accumulated Expenses for 3 consecutive years, with $73000.0 as the latest value for Q4 2025.

  • For Q4 2025, Other Accumulated Expenses fell 90.57% year-over-year to $73000.0; the TTM value through Dec 2025 reached $73000.0, down 90.57%, while the annual FY2025 figure was $73000.0, 90.57% down from the prior year.
  • Other Accumulated Expenses hit $73000.0 in Q4 2025 for Artiva Biotherapeutics, down from $442000.0 in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $1.3 million in Q3 2024 and bottomed at $73000.0 in Q2 2025.
  • Average Other Accumulated Expenses over 3 years is $660857.1, with a median of $774000.0 recorded in 2024.
  • Year-over-year, Other Accumulated Expenses crashed 30.21% in 2024 and then plummeted 90.57% in 2025.
  • Artiva Biotherapeutics' Other Accumulated Expenses stood at $1.1 million in 2023, then plummeted by 30.21% to $774000.0 in 2024, then tumbled by 90.57% to $73000.0 in 2025.
  • According to Business Quant data, Other Accumulated Expenses over the past three periods came in at $73000.0, $442000.0, and $73000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.